AnaptysBio (NASDAQ:ANAB) Stock Price Expected to Rise, Truist Financial Analyst Says

AnaptysBio (NASDAQ:ANAB) had its target price raised by stock analysts at Truist Financial from $20.00 to $36.00 in a note issued to investors on Monday, MarketBeat reports. The firm currently has a “hold” rating on the biotechnology company’s stock. Truist Financial’s target price would suggest a potential upside of 7.27% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, October 8th. Guggenheim raised their price target on shares of AnaptysBio from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Barclays began coverage on shares of AnaptysBio in a report on Monday, October 13th. They issued an “overweight” rating and a $78.00 price objective on the stock. JPMorgan Chase & Co. increased their target price on shares of AnaptysBio from $42.00 to $80.00 and gave the stock an “overweight” rating in a report on Thursday, July 24th. Finally, Wedbush raised their target price on shares of AnaptysBio from $45.00 to $70.00 and gave the company an “outperform” rating in a research report on Wednesday, October 15th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $59.40.

AnaptysBio Trading Down 1.2%

Shares of NASDAQ ANAB opened at $33.56 on Monday. The firm has a market cap of $929.28 million, a PE ratio of -11.90 and a beta of 0.16. AnaptysBio has a 1-year low of $12.21 and a 1-year high of $40.96. The company has a fifty day moving average price of $29.35 and a 200 day moving average price of $24.92.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $1.58. The firm had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%. Equities research analysts forecast that AnaptysBio will post -6.08 EPS for the current year.

Institutional Trading of AnaptysBio

A number of large investors have recently added to or reduced their stakes in the company. Bessemer Group Inc. increased its stake in shares of AnaptysBio by 950.0% during the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 1,292 shares during the last quarter. US Bancorp DE lifted its stake in AnaptysBio by 126.5% in the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 979 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in AnaptysBio by 175.0% during the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,377 shares during the period. Osaic Holdings Inc. grew its holdings in AnaptysBio by 11,630.0% during the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 2,326 shares during the period. Finally, Brooklyn Investment Group increased its position in AnaptysBio by 1,779.9% during the first quarter. Brooklyn Investment Group now owns 6,373 shares of the biotechnology company’s stock worth $118,000 after buying an additional 6,034 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.